Skip to search formSkip to main contentSkip to account menu

KNI 764

Known as: KNI-764, KNI764 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AmidesThiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
A series of HIV protease inhibitor based on the allophenylnorstatine structure with various P(2)' moieties were synthesized… 
2007
2007
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
2006
2006
Optimization and Computational Evaluation of a Series of Potential Active Site Inhibitors of the V82F/I84V Drug‐resistant Mutant of HIV‐1 Protease: an Application of the Relaxed Complex Method of…
The Relaxed Complex method, an approach to structure‐based drug design that incorporates the flexibilities of both the ligand and… 
2004
2004
Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
Highly Cited
2004
Highly Cited
2004
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV‐1 protease
The efficacy of HIV‐1 protease inhibition therapies is often compromised by the appearance of mutations in the protease molecule… 
Highly Cited
2002
Highly Cited
2002
Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 protease
Amprenavir is one of six protease inhibitors presently approved for clinical use in the therapeutic treatment of AIDS… 
Highly Cited
2002
Highly Cited
2002
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
The vast majority of HIV-1 infections worldwide are caused by the C and A viral subtypes rather than the B subtype prevalent in… 
Highly Cited
2001
Highly Cited
2001
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
KNI-764 is a powerful HIV-1 protease inhibitor with a reported low susceptibility to the effects of protease mutations commonly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)